Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome. [Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de piernas inquietas.]

Next Previous
Search
Trial Profile

Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome. [Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de piernas inquietas.]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pregabalin (Primary) ; Pramipexole
  • Indications Restless legs syndrome
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Feb 2014 Results published in the New England Journal of Medicine.
    • 28 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology.
    • 16 Dec 2011 Primary endpoint 'International-Restless-Legs-Scale' has been met, according to a Pfizer media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top